DNA

SafeTraces Selected as a Prime Performer for ARPA-H Building Resilient Environments for Air and Total Health (BREATHE) Program on Other Transaction Agreement up to $39 Million

Pioneering Dual-Use Technology Company Will Lead World-Class Team to Develop and Deploy Real-Time Biosensors, Risk Assessment Software, and Automated Building...

Epigenica AB Launches the Groundbreaking EpiFinder™ GenomePro – Unlocking the Epigenome with Unprecedented High Throughput and Multiplexing Features

SOLNA, Sweden, Sept. 30, 2025 /PRNewswire/ -- Epigenica AB, the leader in epigenomic innovation, proudly announces the launch of the...

SumHealth and Nucleus Genomics Partner to Bring Whole-Genome DNA Testing Into Healthcare Infrastructure

Partnership Makes Advanced, Clinical-Grade Genetic Insights Affordable and Accessible Through Hospitals, Pharmacies and Healthcare Systems Nationwide CHARLOTTE, NORTH CAROLINA /...

SumHealth and Nucleus Genomics Partner to Bring Whole-Genome DNA Testing Into Healthcare Infrastructure

Partnership Makes Advanced, Clinical-Grade Genetic Insights Affordable and Accessible Through Hospitals, Pharmacies and Healthcare Systems Nationwide CHARLOTTE, NORTH CAROLINA /...

Embleema Awarded $5M Department of Defense Contract. Partners With GRAVL and Aria Diagnostics to Create Global Pathogen Bio Surveillance Infrastructure

BOSTON, Sept. 29, 2025 /PRNewswire/ -- Embleema, in partnership with GRAVL and Aria Diagnostics (ARIA), has secured a $5 million...

Onco-Innovations Advances Preclinical Program as Nucro-Technics Begins Analytical Development for PNKP Technology

VANCOUVER, BC / ACCESS Newswire / September 29, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H)(WKN:A3EKSZ) ("Onco" or the "Company") is pleased...

InVita Healthcare Technologies and Alaska Department of Public Safety Mark One-Year Milestone of Forensic Science Hit Outcome Tracking System

BALTIMORE, Sept. 25, 2025 /PRNewswire/ -- InVita Healthcare Technologies, a leading provider of specialized software solutions supporting the advancement of...

Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”),...

error: Content is protected !!